LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that it has demonstrated that iSPERSE™, its inhaled drug platform, shows superiority in delivering an effective therapeutic dose of the active ingredients in Advair®, salmeterol and fluticasone, compared to conventional lactose blend Advair. These data from in vitro studies show the potential of iSPERSE, a proprietary cationic salt formulation inhaled as a dry powder, to efficiently deliver consistent doses, which can have relevance to patients having lower or impaired lung function. Based on these and other data, Pulmatrix is now advancing a number of proprietary iSPERSE drug formulation candidates including small molecules, combinations and biologics in a variety of therapeutic areas, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma, idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and non-CF bronchiectasis, as well as pursuing partnerships for iSPERSE.
